Who are salbutamol + ipratropium bromide nebules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Albuterol, ipratropium bromide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/salbutamol-ipratropium-bromide-nebules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

salbutamol + ipratropium bromide nebules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

salbutamol + ipratropium bromide nebules (salbutamol + ipratropium bromide nebules) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination bronchodilator (beta-2 agonist + anticholinergic). Area: Respiratory.

marketed Combination bronchodilator (beta-2 agonist + anticholinergic) Beta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

salbutamol + ipratropium bromide nebules (salbutamol + ipratropium bromide nebules) — Imperial College London. Salbutamol and ipratropium bromide work together as a combination bronchodilator—salbutamol activates beta-2 adrenergic receptors to relax airway smooth muscle, while ipratropium blocks muscarinic acetylcholine receptors to prevent bronchoconstriction.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
salbutamol + ipratropium bromide nebules TARGET	salbutamol + ipratropium bromide nebules	Imperial College London	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium)
Albuterol, ipratropium bromide	Albuterol, ipratropium bromide	Children's Hospital of Philadelphia	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination bronchodilator (beta-2 agonist + anticholinergic) class)

Children's Hospital of Philadelphia · 1 drug in this class
Imperial College London · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). salbutamol + ipratropium bromide nebules — Competitive Intelligence Brief. https://druglandscape.com/ci/salbutamol-ipratropium-bromide-nebules. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab